| Catherine Schmidt, DPT | |
|
50 27th St W, Suite B, Billings, MT 59102-8601 | |
| (406) 651-9099 | |
| (406) 651-4332 |
| Full Name | Catherine Schmidt |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 50 27th St W, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467900662 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 11206 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Catherine Schmidt, DPT Po Box 5718, Suite B, Kalispell, MT 59903-5718 Ph: (855) 456-7146 | Catherine Schmidt, DPT 50 27th St W, Suite B, Billings, MT 59102-8601 Ph: (406) 651-9099 |
News Archive
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
Calypte Biomedical Corporation, the developer, manufacturer and marketer of the Aware HIV-1/2 OMT (oral fluid) HIV test, announced today that it has been awarded a tax credit of $244,479 under U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.
Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm have reached an agreement with AstraZeneca to take compound AZD-3965 a first-of-its-kind experimental drug to potentially treat a range of cancers into clinical trial.
The University of Dundee's Drug Discovery Unit has announced a multi-million-pound partnership with Korea-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson's disease.
› Verified 2 days ago
Amanda Newbern Langve, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Jonathan W Griffith, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N Ste 140w, Billings, MT 59101 Phone: 406-237-5050 Fax: 406-238-6599 | |
Michael L Kelsey, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3307 Grand Ave, Suite 203, Billings, MT 59102 Phone: 406-655-9060 Fax: 406-655-9065 | |
Garett Cohl Schild, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2825 8th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Logan Yurt, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4652 David Mark Trl, Billings, MT 59101 Phone: 406-861-5466 | |
Bridget Susan Cannon, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2825 8th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Joseph Bloyder, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2702 8th Ave N, Billings, MT 59101 Phone: 406-238-2500 |